Knockdown of Tripartite-59 (TRIM59) Inhibits Cellular Proliferation and Migration in Human Cervical Cancer Cells

被引:42
作者
Aierken, Gulijiahan [1 ]
Seyiti, Ayinuer [1 ]
Alifu, Mayinuer [1 ]
Kuerban, Gulina [1 ]
机构
[1] Xinjiang Med Univ, Affiliated Tumor Hosp, Dept Gynecol, 789 Suzhou Rd, Xinjiang 830011, Peoples R China
关键词
TRIM59; Proliferation; Migration; Invasion; Cervical cancer; E3 UBIQUITIN LIGASE; PROTEINS; ACTIVATION; REVEALS; ENCODES; MOTIF; GENE;
D O I
10.3727/096504016X14741511303522
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The tripartite motif (TRIM) family of proteins is a class of highly conservative proteins that have been implicated in multiple processes. TRIM59, one member of the TRIM family, has now received recognition as a key regulator in the development and progression of human diseases. However, its role in human tumorigenesis has remained largely unknown. In this study, the effects of TRIM59 expression on cell proliferation and migration were investigated in human cervical cancer cells. The expression of TRIM59 in clinical cervical cancer tissues and cervical cancer cells was initially determined by RT-PCR and Western blot. Specific shRNA against TRIM59 was then employed to knock down the expression of TRIM59 in cervical cancer lines HeLa and SiHa. The effects of TRIM59 knockdown on cell proliferation was assessed by MTT assay and colony formation assay. Transwell assay was conducted to reveal cell migration and invasion abilities before and after TRIM59 knockdown. Our results showed that the expression of TRIM59 was significantly elevated in cervical cancers. Knockdown of TRIM59 significantly inhibited cell proliferation and colony formation as well as cell migration and invasion abilities in cervical cancer HeLa and SiHa cells. Cell cycle progression analysis showed that TRIM59-depleted cells preferred to accumulate in the S phase. These data suggest that TRIM59 is a potential target that promotes the progression of cervical cancer.
引用
收藏
页码:381 / 388
页数:8
相关论文
共 27 条
[1]   Deficiency in ubiquitin ligase TRIM2 causes accumulation of neurofilament light chain and neurodegeneration [J].
Balastik, Martin ;
Ferraguti, Francesco ;
Silva, Andre Pires-da ;
Lee, Tae Ho ;
Alvarez-Bolado, Gonzalo ;
Lu, Kun Ping ;
Gruss, Peter .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (33) :12016-12021
[2]   Treatment of climacteric symptoms in survivors of gynaecological cancer [J].
Biglia, Nicoletta ;
Bounous, Valentina Elisabetta ;
Sgro, Luca Giuseppe ;
D'Alonzo, Marta ;
Gallo, Martina .
MATURITAS, 2015, 82 (03) :296-298
[3]  
Cambiaghi V, 2012, ADV EXP MED BIOL, V770, P77
[4]   RAS and RHO GTPases in G1-phase cell-cycle regulation [J].
Coleman, ML ;
Marshall, CJ ;
Olson, MF .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2004, 5 (05) :355-366
[5]   RING Domain E3 Ubiquitin Ligases [J].
Deshaies, Raymond J. ;
Joazeiro, Claudio A. P. .
ANNUAL REVIEW OF BIOCHEMISTRY, 2009, 78 :399-434
[6]   THE PML-RAR-ALPHA FUSION MESSENGER-RNA GENERATED BY THE T(15-17) TRANSLOCATION IN ACUTE PROMYELOCYTIC LEUKEMIA ENCODES A FUNCTIONALLY ALTERED RAR [J].
DETHE, H ;
LAVAU, C ;
MARCHIO, A ;
CHOMIENNE, C ;
DEGOS, L ;
DEJEAN, A .
CELL, 1991, 66 (04) :675-684
[7]   Determinants of cervical cancer rates in developing countries [J].
Drain, PK ;
Holmes, KK ;
Hughes, JP ;
Koutsky, LA .
INTERNATIONAL JOURNAL OF CANCER, 2002, 100 (02) :199-205
[8]   Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none [J].
El-Zein, Mariam ;
Richardson, Lyndsay ;
Franco, Eduardo L. .
JOURNAL OF CLINICAL VIROLOGY, 2016, 76 :S62-S68
[9]   TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity [J].
Gack, Michaela U. ;
Shin, Young C. ;
Joo, Chul-Hyun ;
Urano, Tomohiko ;
Liang, Chengyu ;
Sun, Lijun ;
Takeuchi, Osamu ;
Akira, Shizuo ;
Chen, Zhijian ;
Inoue, Satoshi ;
Jung, Jae U. .
NATURE, 2007, 446 (7138) :916-U2
[10]   Management of Squamous Cancer Metastatic to Cervical Nodes With an Unknown Primary Site [J].
Galloway, Thomas J. ;
Ridge, John A. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29) :3328-+